Devera Pine

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

Recent advances in the characterization of the molecular genetic defects underlying AML, as well as in novel formulations of therapies, are offering hope for improved outcomes.

The introduction of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia has dramatically changed the course of the disease.

The development of targeted agents aimed at aurora kinases has proceeded slowly, and the future may lie in combination therapies.

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.

To date, no studies of novel therapies combined with docetaxel and prednisone have demonstrated improvement in their designated endpoints. However, several promising combination trials are ongoing.

Adjuvant chemotherapy improves disease-free and overall survival in many--but not all--patients with breast cancer.

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.